Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 226.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 413,795 shares of the company’s stock after buying an additional 287,163 shares during the period. GSA Capital Partners LLP’s holdings in Aerovate Therapeutics were worth $865,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Deerfield Management Company L.P. Series C purchased a new stake in Aerovate Therapeutics during the 2nd quarter worth approximately $2,343,000. Vanguard Group Inc. lifted its position in Aerovate Therapeutics by 7.2% during the 1st quarter. Vanguard Group Inc. now owns 672,275 shares of the company’s stock worth $19,879,000 after acquiring an additional 45,444 shares during the period. Ikarian Capital LLC acquired a new position in shares of Aerovate Therapeutics in the first quarter valued at about $10,881,000. Affinity Asset Advisors LLC purchased a new position in shares of Aerovate Therapeutics in the second quarter worth about $332,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Aerovate Therapeutics during the second quarter worth about $298,000.

Aerovate Therapeutics Trading Down 1.2 %

Shares of NASDAQ:AVTE opened at $2.53 on Friday. Aerovate Therapeutics, Inc. has a twelve month low of $1.25 and a twelve month high of $32.42. The company has a market cap of $73.05 million, a PE ratio of -0.85 and a beta of 1.00. The company’s 50 day moving average is $2.21 and its 200 day moving average is $6.09.

Aerovate Therapeutics (NASDAQ:AVTE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.03. Equities research analysts predict that Aerovate Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.